← All trials
NCT06049940
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2023
- Primary completion
- Sep 1, 2024
- Completion date
- Mar 30, 2025
- First posted
- Sep 22, 2023
- Last posted
- Oct 18, 2023
- Enrollment
- 1260
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China National Pharmaceutical GroupLead sponsor
- Government of ChinaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.